Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice

Biomedical Journal

Volumn 37, Issue 5, 2014, Pages 326-330

  Liang, Chih Ming ^a   Cheng, Jen Wen ^a   Kuo, Chung Mou ^a   Chang, Kuo Chin ^a   Wu, Keng Liang ^a   Tai, Wei Chen ^a   Chiu, King Wah ^a   Chiou, Shue Shian ^a   Lin, Ming Tsung ^a   Hu, Tsung Hui ^a   Chuah, Seng Kee ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

7 day levofloxacin containing triple therapy; fluoroquinolone; second line anti Helicobacter pylori therapy

Indexed keywords

AMOXICILLIN; ESOMEPRAZOLE; LEVOFLOXACIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; BACTERIUM CULTURE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; TAIWANESE; TREATMENT DURATION; UREA BREATH TEST; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; MIDDLE AGED; PROCEDURES; TAIWAN; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LEVOFLOXACIN; MALE; METRONIDAZOLE; MIDDLE AGED; TAIWAN; TREATMENT OUTCOME;

EID: 84908655578     PISSN: 23194170     EISSN: None     Source Type: Journal    
DOI: 10.4103/2319-4170.125650     Document Type: Article

References (30)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter infection. The Maastricht III Consensus Report. Gut 2007;56:772-81
2. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, et al. High efficacy of 1-week doxycycline-And amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther 2004;19:789-95
3. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502
4. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003;35:523-8
5. Zullo A, Hassan C, Lorenzetti R, Morini S. Helicobacter pylori eradication: Do we have another ace up our sleeve?. Dig Liver Dis 2001;33:805-6
6. Croom KF, Goh KL. Levofloxacin: A review of its use in the treatment of bacterial infections in the United States. Drugs 2003;63:2769-802
7. Wong WM, Gu Q, Chu KM, Yee YK, Fung FM, Tong TS, et al. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection. Aliment Pharmacol Ther 2006;23:421-7
8. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: A meta-Analysis. Am J Gastroenterol 2006;101:488-96
9. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol 2011;17:3971-5
10. Tanaka M, Isogai E, Isogai H, Hayashi S, Hirose K, Kimura K, et al. Synergic effect of quinolone antibacterial agents and proton pump inhibitors on Helicobacter pylori. J Antimicrob Chemother 2002;49:1039-40
11. Kuo CH, Hu HM, Kuo FC, Hsu PI, Chen A, Yu FJ, et al. Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: A randomized controlled trial. J Antimicrob Chemother 2009;63:1017-24
12. Cheng HC, Chang WL, Chen WY, Yang HB, Wu JJ, Sheu BS. Levofloxacin-containing triple therapy to eradicate the persistent H. pylori after a failed conventional triple therapy. Helicobacter 2007;12:359-63
13. Hu TH, Chuah SK, Hsu PI, Wu DC, Tai WC, Chiu YC, et al. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori. Am J Med Sci 2011;342:177-81
14. Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, et al. Randomized comparison of two non-Bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter 2012;17:216-23
15. Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, et al. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatment for helicobacter pylori infection: A randomized comparative trial with crossover design. Gut 2010;59:572-8
16. Hsu PI, Lai KH, Tseng HH, Lo GH, Lo CC, Lin CK, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001;15:195-201
17. Yakoob J, Abid S, Jafri W, Abbas Z, Islam M, Ahmad Z. Comparison of biopsy-based methods for the detection of Helicobacter pylori infection. Br J Biomed Sci 2006;63:159-62
18. Peng NJ, Lai KH, Liu RS, Lee SC, Tsay DG, Lo CC, et al. Clinical significance of oral urease in the diagnosis of H. pylori infection by 13C-urea breath test. Dig Dis Sci 2001;46:1772-8
19. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25
20. Bilardi C, Dulbecco P, Zentilin P, Reglioni S, Iiritano E, Parodi A, et al. A 10-day levofloxacin-based therapy in patients with resistant Helicobacter pylori infection: A controlled trial. Clin Gastroenterol Hepatol 2004;2:997-1002
21. Schrauwen RW, Janssen MJ, de Boer WA. Seven-day PPI-Triple therapy with levofloxacin is very effective for Helicobacter pylori eradication. Neth J Med 2009;67:96-101
22. Gisbert JP, Molina-Infante J, Marin AC, Vinagre G, Barrio J, McNicholl AG. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. Scand J Gastroenterol 2013;48:652-6
23. Miehlke S, Krasz S, Schneider-Brachert W, Kuhlisch E, Berning M, Madisch A, et al. Randomized days of esomeprazole, moxifloxacin, and amoxicillin for trial on 14 versus 7 second-line or rescue treatment of Helicobacter pylori infection. Helicobacter 2011;16:420-6
24. De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects. Curr Med Chem 2001;8:371-4
25. Marzio L, Coraggio D, Capodicasa S, Grossi L, Cappello G. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and esomeprazole. Helicobacter 2006;11:237-42
26. De Francesco V, Giorgio F, Hassan C, Manes G, Vannella L, Panella C, et al. Worldwide H. pylori antibiotic resistance: A systematic review. J Gastrointestin Liver Dis 2010;19:409-14
27. Sheu BS, Kao AW, Cheng HC, Hunag SF, Chen TW, Lu CC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21:283-8
28. Shimizu T, Ochiai H, Asell F, Shimizu H, Saitoh R, Hama Y, et al. Bioinformatics research on inter-racial difference in Drug metabolism. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab Pharmacokinet 2003;18:48-70
29. Madan A, Holland S, Humbert JE, Benitz WE. Racial differences in birth weight of term infants in a northern California population. J Perinatol 2002;22:230-5
30. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8